Market cap
$11.9m
End-of-day close multiplied by current shares on issue.
Result releasedAnnolyse analysis published
Revenue grew 93.5% to $2.9m but cash fell to $0.001m and borrowings rose 55.9%, exposing acute liquidity strain.
Revenue context before the current result.
Operating profit margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Market context
These ratios pair a market close from around the result date with verified filing data. An unavailable metric means the required inputs were missing or unsuitable for comparison.
The latest close and share count context for the market price.
Market cap
$11.9m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.01
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not meaningful when recent EBITDA is negative.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
2.79x
Market value compared with latest reported equity.
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
FY26 vs FY25
Revenue
$2.9m
Caveat: metric quality flags apply; use this value with basis context.
Net profit after tax
−$3.4m
Caveat: metric quality flags apply; use this value with basis context.
Net cash inflow from operating activities
−$3m
Caveat: metric quality flags apply; use this value with basis context.
Cash and cash equivalents
$0m
-99.6% ↓ vs $0.24m
Total assets
$7.2m
Caveat: metric quality flags apply; use this value with basis context.
Analysis ofRUA FY26Result releasedAnnolyse analysis published
What changed
This matters more than the headline top line because it signals the company is funding its losses almost entirely with debt rather than cash reserves.
Total revenue and other income rose 93.5% to $2.9m from $1.5m, while revenue from customers rose 71% to $2.58m on the company's own reporting — these are different revenue bases from the same release and should not be treated as interchangeable. The pre-tax loss narrowed 2.8% to $3.4m from $3.5m, but operating cash outflow widened to $3.0m from $2.8m over the same period.
Trade debtors and inventories both collapsed to near zero (down 99.5% and 99.8% respectively), consistent with the disclosed discontinued-operation event flag, though the extraction does not quantify a separate discontinued-operation result.
What matters
Total assets of $7.2m sit at the lower edge of Annolyse's historical range, against a three-period mean of $20.4m, reinforcing that the balance sheet has thinned materially rather than simply fluctuated within a normal band.
The loss narrowed on a statutory basis, but the cash outflow from operations widened by 6.2% to $3.0m, so the P&L improvement did not translate into a smaller cash burn — an earnings-quality gap that matters because it means the reported loss understates the cash pressure investors should track.
The near-total disappearance of trade debtors and inventories from the balance sheet, alongside the discontinued-operation overlay, suggests a structural change in what the group now holds and sells, but the filing does not reconcile the size or driver of that change.
Expectations
The half-year split shows $1.3m of statutory revenue in the first half against $1.6m implied in the second half (45.6% first-half share), indicating second-half weighting on a reported basis, though this should not be read as an underlying trading-momentum signal absent further disclosure.
Without a stated cash runway or funding target, investors cannot assess whether the current borrowing increase is a one-off bridge or the start of a recurring reliance on debt.
Quality of result
Net tangible assets per share of $0.01 point to a thin residual buffer, and the near-zero cash position means any delay in receivables collection or supplier terms could quickly strain operations.
Revenue growth is real on both bases disclosed, but its durability depends on customer concentration and contract timing that are not detailed here; the UK export agreement cited in commentary is a named driver of future growth rather than a component already reconciled into FY26 revenue.
Unresolved
This briefing cannot assess the specific terms, maturity, or covenant conditions attached to the increased borrowings, or the precise financial detail behind the discontinued-operation overlay.
Chat
Ask follow-up questions about Rua Bioscience's FY26 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
FY26 Preliminary Financial Results
FY26 / financial reportFY26 Preliminary Financial Results Announcement
FY26 / results announcementRua Bioscience FY25 Annual Report
FY25 / financial reportRua Bioscience FY25 Annual Report Announcement
FY25 / results announcementHalf-Year Financial Results Announcement
HY26 / results announcementHalf-Year Financial Statements
HY26 / financial reportASM Presentation FY25
FY25 / commentaryASM Presentation FY25
HY26 / commentaryRelated insights
Compare this result's metrics with other covered NZX companies.
Earnings quality and statutory distortions
This result includes a statutory earnings-quality distortion flag.
Revenue growth context
Revenue growth was 93.5% for this reporting period.
Leverage and balance-sheet risk
Net debt / EBITDA is -0.56x, -0.30x versus the prior comparable period.
Working-capital pressure
Inventory days were 0 days, -98 days versus the prior comparable period.
Get the next Rua Bioscience briefing and related NZX reporting-season updates by email.